Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) collected $7.0M revenue from collaborators

      

Posted By - Marcia Kelsey

On Yesterday, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) +2.08% in trading session and finally closed at $72.56. The firm after opening the first trading session at $71.43 Over the one year trading period, the stock has an above price of $124.21 and it’s below is recorded at $60.27. The company has a market cap of $7.73B. The company most recent volume stood at 1,112,912 shares as compared to its average volume of 972,395 shares.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), recently stated its consolidated financial results for the first quarter 2019.

2019 is off to a strong start for Alnylam, as we ended the first quarter with a balance sheet of $1.3B and subsequently improved with $800M in additional cash predictable to be received during the second quarter.

In January 2019, Alnylam sold an aggregate of 5,000,000 shares of its ordinary stock through an underwritten public offering at a price to the public of $77.50 per share. As a result of the offering, Alnylam received aggregate net proceeds of about $382M. Alnylam has cash, cash equivalents and marketable debt securities and restricted investments of greater than $2B.

GAAP and Non-GAAP Net Loss
The net loss for the first quarter of 2019 was $181.9M, or $1.73 per share, as contrast to a net loss of $141.2M, or $1.41 per share on both a basic and diluted basis, for the same period in the previous year.

The non-GAAP net loss for the first quarter of 2019 was $149.9M, or $1.42 per share, as contrast to a non-GAAP net loss of $121.6M, or $1.22 per share on both a basic and diluted basis for the same period in the previous year.

Net Revenues from Collaborators
Net revenues from collaborators were $7.0M in the first quarter of 2019 as contrast to $21.9M in the first quarter of 2018.

GAAP and Non-GAAP Research and Development Expenses
GAAP research and development (R&D) expenses were $129.1M in the first quarter of 2019 as contrast to $96.9M in the first quarter of 2018.

Non-GAAP R&D expenses were $113.0M in the first quarter of 2019 as contrast to $86.7M in the first quarter of 2018.

GAAP and Non-GAAP Selling, General and Administrative Expenses
GAAP selling, general and administrative (SG&A) expenses were $89.6M in the first quarter of 2019 as contrast to $72.4M in the first quarter of 2018.

Non-GAAP SG&A expenses were $73.7M in the first quarter of 2019 as contrast to $63.0M in the first quarter of 2018.